



The CNX Nifty ended at 17221.40, down by 103.50 points or 0.60% after trading in a range of 17192.20 and 17351.20

Ending the session below the crucial 17250 levels indicate further weakness. Hence, staying cautious is recommended. Immediate trading range is likely to be 17250-17550. On the Nifty hourly chart, the Index was seen making some sort of base, finding support at the crucial 17250 support level. Hence, staying cautious on rise is advised. Immediate trading range is likely to be 17000-17550.

A consecutive day below 17250 levels may indicate further weakness.

Nifty Crucial Supports & Resistances-

Supports- 17000-17250 Resistances- 17500, 17550

Key Contents	Page No.
Domestic News	4

Nifty Intraday Chart



Market in Retrospect

India's stock benchmarks fell for the fourth consecutive session, dragged by losses in information technology, metal and reality stocks, as markets ended at day's low in a volatile session. Focus now shifts to the crucial U.S. Federal Reserve meeting due later today as rapid tapering of monetary stimulus is expected amid elevated inflation levels.

Nifty index ended 0.60% lower at 17,221. The broader markets represented by the NIFTY 500 Index ended 0.60% lower, ending at 14,953. Among the sectorial indices, NIFTY Auto was the only top gainer, gaining by 0.49%. NIFTY Realty was the top loser, losing by 1.89%.

Sun Pharma was the top gainer, gaining by 2.52%, followed by Kotak Bank and M&M gained by 1.47% & 1.12% respectively. Bajaj Finance was the top loser, losing by 3.09%, followed by Bajaj Finserv and Adani ports & SE which fell by 2.70% & 2.38% respectively.

The Advance : Decline ratio stood at 848:1231

Market Turnover (In Crore) 15-12-2021

Name	Last	Previous
NSE Cash	52170.41	57813.34
NSE F&O	6613755.24	6272737.67
BSE Cash	4,141.74	4,390.31
BSE F&O*	133.86	91.90

FII Derivatives Flow (In Crore) 14-12-2021*

Instrument	Purchase	Sale	Net
Index Future	3493.57	5150.22	1656.65
Index Option	411590.20	414844.13	3253.93
Stock Future	11355.70	13537.30	2181.6
Stock Option	11645.41	11707.36	61.95

Institutional Flow (In Crore) 15-12-2021

Institution	Purchase	Sale	Net
FII	5373.66	8780.70	3407.04
DII	5721.32	4168.31	1553.01

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Sun Pharma	2.52	2.32	6231786	2760203
Kotak Bank	1.47	2.76	5305747	5406267
M&M	1.12	0.65	3208613	2904326
Maruti Suzuki	1.00	1.79	529018	721954
Hero Motocorp	0.94	0.66	470021	347229

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
ITC	1.99	0.40	34653042	28565880
ONGC	2.01	3.00	10361033	11301580
Adani Ports & SE	2.38	2.09	4673906	5452660
Bajaj Finserv	2.70	5.45	253221	237987
Bajaj Finance	3.09	6.99	1817528	1146773

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

*Data not updated till 7pm

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	57788.03	329.06	0.57	1.47	4.83	1.59	24.91
Nifty	17221.40	103.50	0.60	1.42	4.90	1.70	26.93
BSE M Cap	25327.12	149.74	0.59	0.72	4.34	0.44	42.82
BSE S Cap	29244.83	101.29	0.35	1.60	0.24	3.40	65.26
Nifty MC 100	30888.55	178.70	0.58	0.39	3.56	2.36	49.45
BSE Auto	24930.26	123.11	0.50	0.03	5.06	7.51	20.42
BSE Capgoods	28666.30	25.75	0.09	2.86	1.13	9.61	57.38
BSE FMCG	13729.54	70.38	0.51	0.46	4.49	8.08	9.36
BSE Metal	19606.40	202.49	1.02	0.07	0.90	7.24	72.71
BSE Oil&Gas	18089.30	158.14	0.87	0.43	5.38	2.01	24.16
BSE Healthcare	25170.05	87.43	0.35	0.46	2.00	6.36	19.07
BSE Power	3619.14	23.50	0.65	1.71	1.54	15.51	73.92
BSE Realty	3955.97	71.81	1.78	0.40	8.32	17.57	73.36
BSE ConsDur	43091.01	62.73	0.15	1.08	5.37	4.57	50.51
BSE Bank	41864.15	55.28	0.13	1.22	5.33	0.49	19.07
BSE IT	35056.62	366.44	1.03	0.60	1.16	0.84	54.95

Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.44	0.00	0.12	5.15	10.63	11.09	58.90
UK	0.75	0.03	3.87	2.97	21.99	3.34	189.23
Brazil	4.63	0.03	0.68	0.98	0.30	19.01	40.48
Japan	0.05	0.00	1.92	6.00	19.70	47.22	960.00
Australia	1.56	0.02	1.23	3.70	11.67	29.25	61.99
India	6.36	0.01	0.13	0.09	0.33	3.26	8.10
Switzerland	0.28	0.01	3.40	7.17	134.71	14.06	50.52
Germany	0.36	0.01	2.17	15.34	57.64	17.97	40.92

Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	76.23	0.36	0.47	1.02	2.29	3.59	3.40
USD Index	96.53	0.04	0.04	0.66	1.18	4.30	6.70
YUAN	6.37	0.00	0.03	0.33	0.28	1.05	2.73
GBP	1.33	0.00	0.17	0.37	1.22	4.24	1.54
EUR	1.13	0.00	0.06	0.68	0.90	4.66	7.28
YEN	113.82	0.12	0.11	0.13	0.26	3.90	8.92

Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2932.00	284.00	8.83	12.53	6.27	30.73	130.32
Baltic Dirty	795.00	7.00	0.89	3.11	2.09	28.64	82.76
SG Dubai HY	6.70	0.03	0.45	15.92	74.03	362.07	3426.32

Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	35544.18	106.77	0.30	0.49	1.51	2.10	17.70
Nasdaq	15237.64	175.64	1.14	2.86	3.89	0.50	20.98
S&P 500	4634.09	34.88	0.75	1.12	1.04	3.42	25.43
FTSE100	7202.68	18.49	0.26	1.87	2.06	2.62	10.55
CAC40	6942.81	45.77	0.66	1.05	2.63	5.43	25.51
DAX	15504.40	49.16	0.32	1.18	4.00	0.73	16.01
Mexico IPC	51241.47	822.30	1.63	0.63	0.37	1.82	17.68
Brazil Bovespa	106759.9	623.40	0.58	0.74	0.40	7.22	8.08
Russian RTS	1559.59	10.94	0.71	3.29	12.93	11.71	12.18
Japan Nikkei	28459.72	27.08	0.10	1.39	4.42	6.73	6.64
Hang Seng	23420.76	215.19	0.91	2.40	7.76	6.44	10.63
Taiwan Index	17660.10	60.73	0.35	0.97	0.15	1.76	25.53
Shanghai Comp	3647.63	13.90	0.38	0.28	3.24	0.24	8.33
KOSPI	2989.39	1.44	0.05	0.41	0.34	5.20	8.44
Malaysia KLCI	1482.81	1.89	0.13	0.75	2.60	4.66	11.42
Jakarta Comp	6626.26	10.62	0.16	0.34	0.15	8.45	10.25
Philippine SE	7132.58	109.41	1.51	0.21	2.86	3.67	1.32
Thai Exch	1623.66	6.98	0.43	0.89	0.92	0.27	9.91

Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	69.60	1.24	1.75	3.97	14.08	4.30	45.93
BRENT Crude	72.67	1.10	1.49	4.25	10.43	1.10	46.16
Natural Gas	3.84	0.10	2.54	0.71	24.73	32.31	24.54

LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1768.81	1.91	0.11	0.79	5.04	1.40	4.57
Silver(\$/Ounce)	21.77	0.18	0.82	2.98	13.15	8.71	11.14
Aluminium	2626.00	44.20	1.66	0.40	2.67	6.54	29.26
Copper	9406.50	28.50	0.30	2.14	4.42	0.21	21.70
Zinc	3314.25	29.25	0.87	0.79	1.13	9.20	18.04
Lead	2306.00	13.00	0.56	5.03	3.47	1.36	14.19

Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	237.35	0.20	0.08	2.81	5.49	24.82	79.67
Cotton	105.87	0.03	0.03	0.80	7.65	14.31	44.08
Sugar	19.41	0.24	1.22	2.07	1.67	4.20	42.41
Wheat	774.75	12.25	1.56	2.49	7.41	7.05	26.54
Soybean	1261.50	3.00	0.24	0.57	0.57	3.54	20.06

Microfinance loan portfolio grows 5.16 pc to Rs 2.43 lakh crore as on September-end

The gross loan portfolio (GLP) of microfinance industry grew by 5.16 per cent to Rs 2.43 lakh crore as on September 30, 2021 from Rs 2.31 lakh crore in the year-ago period, according to a report by Microfinance Institutions Network (MFIN) on Wednesday. MFIN is an industry association comprising of 58 NBFC-MFIs and 39 associates including banks, small finance banks (SFBs) and NBFCs. The industry served 5.65 crore unique borrowers, through 10.52 crore loan accounts as of September-end. As of September 30, 2021, 13 banks held the largest share of portfolio in micro-credit with total loan outstanding of Rs 1.01 lakh crore, which is 41.52 per cent of total microcredit universe. NBFC-MFIs are the second largest provider of micro-credit with a loan amount outstanding of Rs 82,749 crore, accounting for 33.95 per cent to total industry portfolio. Small finance banks (SFBs) had a total loan amount outstanding of Rs 40,534 crore with a total share of 16.63 per cent. NBFCs accounted for another 6.85 per cent and other MFIs account for 1.05 per cent of the universe.

Sugar mills, distilleries to earn revenue of over Rs 18,000 crore from ethanol sales in 2021-22 season

Sugar mills and distilleries are likely to earn revenue of over Rs 18,000 crore in 2021-22 season by selling ethanol to oil marketing companies (OMC) for blending with petrol. In a written reply to the Lok Sabha, Minister of State for Food and Consumer Affairs Sadhvi Niranjana Jyoti informed that during the last three ethanol supply years 2018-19, 2019-20 and 2020-21, the revenue of about Rs 8,079 crore, Rs 7,823 crore and Rs 13,598 crore, respectively, have been generated by sugar mills/distilleries from the sale of ethanol to OMCs. This has helped sugarcane mills in making timely payment of cane dues of farmers. The minister observed that diversion of excess sugar to ethanol would solve the problem of high inventories of sugar, improve the liquidity of mills thereby, helping in timely payment of cane dues of farmers.

L&T's construction arm bags 'large' order from UP Water & Sanitation Mission

Larsen & Toubro on Wednesday said the water and effluent treatment business of L&T Construction has secured a 'large' order from the Uttar Pradesh government to implement rural water supply projects. This is a repeat order for L&T Construction from the State Water & Sanitation Mission (SWSM), Uttar Pradesh to implement rural water supply projects providing functional house tap connections under the Jal Jeevan Mission. The business has been entrusted to implement rural water supply projects catering to the potable water requirement of 1,900 villages in the Prayagraj revenue division of Prayagraj district. Though the company did not specify the exact value of the contracts, as per its specification a large contract ranges between Rs 2,500 crore and Rs 5,000 crore. The scope of the order comprises construction of tube wells, pump houses cum chlorination rooms, overhead tanks, treatment systems, solar plants, rising main and distribution pipeline network among others. The business is already executing water supply schemes in the districts of Mahoba, Banda, Chitrakoot, Gonda, Varanasi, Lucknow and Sonbhadra for SWSM.

Pfizer confirms COVID pill's results, potency versus omicron

Pfizer on its experimental pill to treat COVID-19 appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms. Separate laboratory testing shows the drug retains its potency against the omicron variant, the company announced, as many experts had predicted. Pfizer tested the antiviral drug against a man-made version of a key protein that omicron uses to reproduce itself. The Food and Drug Administration is expected to soon rule on whether to authorize Pfizer's pill and a competing pill from Merck, which was submitted to regulators several weeks earlier. If granted, the pills would be the first COVID-19 treatments that Americans could pickup at a pharmacy and take at home.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Kilpest India Ltd	Corporate meeting effective 16-12-2021
Motilal Oswal Financial Services Ltd	Corporate meeting effective 16-12-2021
Ipca Laboratories Ltd	Corporate meeting effective 16-12-2021
Aditya Birla Capital Ltd	Corporate meeting effective 16-12-2021
Aditya Birla Money Ltd	Corporate meeting effective 16-12-2021
SOM Distilleries And Breweries Ltd	Corporate meeting effective 16-12-2021
MMTC Ltd	Corporate meeting effective 16-12-2021
Kewal Kiran Clothing Ltd	Stock dividend of INR5 effective 16-12-2021
KHFM Hospitality and Facility Management Services Ltd	Stock dividend of INR 1.03 effective 16-12-2021
Shankar Lal Rampal Dye-Chem Ltd	Stock dividend of INR2 effective 16-12-2021
Earum Pharmaceuticals Ltd	5 for 1 stock split effective 16-12-2021
Quantum Gold Fund	50 for 1 stock split effective 16-12-2021

Domestic Events

- No events

Global Events

- The U.S. Fed Interest Rate Decision.
- The U.S. Housing Starts for November 2021.
- The U.S. Initial Jobless Claims December 11, 2021.
- The U.S. Markit Flash PMI for December 2021.
- Euro Area Markit Flash PMI for December 2021.
- Euro Area Balance of Trade for October 2021
- ECB Interest Rate Decision.
- Japan Balance of Trade for November 2021.
- Japan Jibun Bank Flash PMI for December 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Jaydeb Dey and Deepankar Saha Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

Contact us:

SMIFS Limited. (<https://www.smifs.com/>)

Compliance Officer:

Sudipto Datta,

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: compliance@smifs.com
